News Hub | News Direct

News Release

Van Ness Corridor Emerges as San Francisco’s Premier Medical Destination

The Hoyt Organization

The Van Ness corridor has become one of San Francisco’s most dynamic medical and healthcare destination, anchored by the world-class Sutter Health’s California Pacific Medical Center and supported by an expanding ecosystem of medical office spaces and care providers. A highlight of this transformation is the 45,000 square feet of premium medical office space currently available at 939 Ellis St., making it the largest contiguous medical space on the market in San Francisco today. Strategically located just steps away from Sutter’s Van Ness campus, 939 Ellis offers an unparalleled opportunity for medical groups, specialty clinics, and healthcare innovators looking to establish a presence in the city’s fastest-growing healthcare hub. Ellis’ central location provides convenience for patients commuting from East Bay, the Peninsula, and Marin County. Connectivity to the Van Ness Corridor has never been better with the 2022 launch of the Van Ness Bus Rapid Transit, a 1.96-mile route running north-south featuring dedicated center bus lanes and nine stations. “The synergy between the neighborhood’s thriving healthcare community and access to transportation is reshaping the Van Ness corridor into a one-stop destination for high-quality patient care,” said Kurt Hackett, Vice President of Asset Management with Rethink Healthcare Real Estate, a private investment group that owns 939 Ellis St. “Whether it’s primary care, outpatient specialties, diagnostics, or wellness services, everything patients and providers need is increasingly concentrated in this central, transit oriented neighborhood.” The building, which is already about half occupied by Kaiser Permanente, comes to market amid a notable resurgence in San Francisco’s economy as the city positions itself for a boom in AI investments. The increase in business is being further fueled by the return-to-office trend and a growing belief that San Francisco is on the right track, according to recent surveys. Recently elected Mayor Daniel Lurie has spearheaded many new efforts that are working to bring businesses and visitors back to the world class downtown. As demand for centrally located, modern medical space continues to rise, the Van Ness corridor stands out as a focus for San Francisco’s healthcare future. “We could not be more bullish on this location,” said Jonathan Winer, President of Rethink Healthcare Real Estate. “Not only is San Francisco’s reemergence as a hotbed of business activity a catalyst for those looking to treat patients locally, but the ease of transit has made the Van Ness Corridor a convenient destination for doctors and patients, alike, who are coming from the outskirts of the city or the suburbs.” 939 Ellis St. offers flexible, build-ready medical office suites that can accommodate a range of specialties. It boasts a scenic rooftop terrace and available parking. For leasing inquiries at 939 Ellis St., contact Trask Leonard, president and CEO of Bayside Realty Partners at tleonard@baysiderp.com or Caroline Doyle, senior vice president of Bayside Realty Partners, at cdoyle@baysiderp.com. Contact Details The Hoyt Organization Andrew King +1 914-513-6895 aking@hoytorg.com Company Website https://rethink-capital.com/healthcare-real-estate/

April 23, 2025 10:20 AM Pacific Daylight Time

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Global Markets News

Silexion Therapeutics' (NASDAQ: SLXN) * groundbreaking RNAi therapy showing 70-80% tumor reduction takes major step forward with global manufacturing collaboration; Wall Street analysts reportedly maintain $5 price target representing potential 500% upside as company targets $470B precision medicine market Game-Changing Partnership Announcement In a strategic move that significantly advances its revolutionary cancer treatment pipeline, Silexion Therapeutics (NASDAQ: SLXN) announced today a collaboration with global therapeutics giant Catalent to optimize and manufacture its breakthrough KRAS-targeting therapy SIL204. This partnership represents a critical acceleration toward human clinical trials, expected to begin in the first half of 2026. The collaboration will leverage Catalent's state-of-the-art Limoges, France facility—a European center of excellence for complex biologics formulation—to optimize both systemic and intratumoral delivery formulations of SIL204, supporting Silexion's innovative dual-route strategy targeting both primary tumors and metastases. "Our collaboration with Catalent represents a significant advancement in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "Catalent's expertise in complex formulation development will be instrumental as we work toward our goal of initiating human clinical trials in the first half of 2026." Disrupting the "Undruggable": Silexion's Breakthrough Approach to KRAS Mutations Silexion's technology stands at the frontier of precision oncology, targeting KRAS mutations—long considered the "holy grail" of cancer targets and present in over 90% of pancreatic cancers. While competitors have developed small molecule inhibitors that target only specific KRAS mutations (primarily G12C, found in just 1-2% of pancreatic cancers), Silexion's RNA interference approach silences multiple KRAS mutations at the genetic level. Recent preclinical data revealed SIL204's remarkable efficacy across multiple pancreatic cancer models: 70% reduction in tumor burden in AsPC-1 models (KRAS G12D mutation) Significant dose-dependent tumor reduction in Panc-1 models (KRAS G12D mutation) 80% tumor reduction in BxPC-3 models Most critically, for the first time, Silexion demonstrated SIL204's ability to reduce metastatic spread to secondary organs—a game-changing advancement that could transform treatment paradigms for aggressive pancreatic cancer. Dual-Route Strategy: A Comprehensive Attack on Cancer Silexion recently unveiled its expanded development plan for SIL204, integrating both systemic administration for targeting metastatic progression and intratumoral delivery for attacking primary tumors—a comprehensive approach unique in KRAS-targeted therapies. The orthotopic models used in Silexion's breakthrough studies better represent human pancreatic cancer biology by allowing tumors to develop in their native environment. This stands in contrast to subcutaneous xenograft models, where tumors grow beneath the skin rather than in the organ of origin. This expanded approach is supported by SIL204's demonstrated ability to maintain therapeutic levels for over 56 days from a single administration—an unprecedented achievement in RNAi therapeutics. Massive Market Opportunity in Precision Oncology The partnership with Catalent positions Silexion advantageously within the rapidly growing precision medicine market, projected to surge from $102 billion in 2024 to $470 billion by 2034, growing at a CAGR of 16.5%. Within this broader market, KRAS-driven cancers represent a substantial unmet need, with the market for KRAS inhibitors expected to grow at an impressive 36% CAGR, reaching $10 billion by 2032. Recent years have seen unprecedented consolidation in precision oncology, with big pharma aggressively seeking innovative assets: Pfizer's landmark $43 billion acquisition of Seagen in 2023 AbbVie's $10.1 billion purchase of Immunogen Numerous other multi-billion dollar transactions for targeted oncology assets With major pharmaceutical companies collectively holding over $170 billion in cash reserves, according to reports, the M&A environment remains highly favorable for innovative companies developing breakthrough cancer therapeutics. Wall Street's Bullish Outlook: Over 500% Potential Upside Wall Street analysts appear to recognize Silexion's potential, with Maxim Group maintaining a Buy rating and a $5 price target—representing a remarkable premium of over ~500% from today's pre market price. This seemingly bullish stance reflects confidence in Silexion's differentiated technology, promising preclinical data, and clear strategic roadmap. Silexion's partnership with Catalent adds credibility to its development roadmap, which includes toxicology and pharmacodynamic studies throughout 2025, regulatory submissions to the Israel Ministry of Health in H2 2025 and the European Union in H1 2026, and the initiation of human clinical trials in 2026. A Potential Industry Game-Changer to Watch Silexion Therapeutics stands at a pivotal moment in its development journey. With groundbreaking preclinical data demonstrating efficacy against both primary tumors and metastases, a clear strategic roadmap to clinical trials, and now a global manufacturing partnership with Catalent, the company is positioned at the intersection of high unmet medical need and significant market opportunity. As pancreatic cancer remains one of the deadliest malignancies with a dismal five-year survival rate below 13%, Silexion's innovative approach targeting multiple KRAS mutations could represent a transformative advancement in treatment paradigms—potentially reshaping the landscape for one of oncology's most challenging diseases. For investors seeking exposure to next-generation precision oncology, Silexion represents a unique opportunity to participate in the development of a potentially disruptive technology addressing one of medicine's most significant challenges. News Highlights from Silexion: - Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models *Disclaimer: This article was written and published by Wall Street Wire™, a promotional content and distribution brand and network. Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. The operators of Wall Street Wire network are not registered brokers, dealers, or investment advisers. This article contains and is a form of paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This article has not been reviewed or approved by Silexion Therapeutics prior to publication. The information in this article is based on publicly available news reports and filings which have not been independently verified by us. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Wall Street Wire | Coverage Desk media.globalmarkets@gmail.com

April 23, 2025 09:54 AM Eastern Daylight Time

BioLumic Oversubscribed Funding Round Accelerates a New Category of Non-GMO Seed Traits

BioLumic

BioLumic Inc., a pioneer in seed trait innovation, today announced the close of its oversubscribed Series B Extension, securing $8.3 million USD from new and existing investors, including Ki Tua Fund, Azolla Ventures, and iSelect Fund. The new capital will accelerate the commercial growth of a breakthrough category of seed traits – xTraits™ – the world’s first seed traits activated purely by precise light signals. The round attracted a strategic investor group led by the Ki Tua Fund—an early-stage venture fund backed by global dairy leader Fonterra—alongside Azolla Ventures, a climate-focused agtech investor, and iSelect Fund, a U.S.-based food, agriculture, and healthcare innovation fund. They join existing backers DYDX Capital, Rabo Ventures, AgriZero, MIG Angels, Icehouse Ventures, and OurCrowd, underscoring broad industry validation and global reach. BioLumic is advancing high-value traits in corn, rice, soybean, and forage grasses for pasture-based dairy systems. The company’s xTraits™ technology enables seed company partners to deliver enhanced, non-GMO and non-GE traits up to 90% faster and more cost-effectively than traditional methods—unlocking new value across the agricultural supply chain. The proprietary xTraits™ platform uses targeted UV light signals to program genetic expression in plants—without altering their DNA and without the regulatory hurdles of genetic modification. This new class of seed traits significantly improves yield, stress resilience, and nutritional composition; stacks with existing biotech traits; and dramatically reduces the time, cost, and risk of trait development. “Seed traits are powerful and essential, but the innovation cycle is broken. Developing new traits takes too much time and capital to keep pace with market demand — creating tremendous risk for both seed companies and farmers,” said Steve Sibulkin, CEO of BioLumic. “The xTraits™ platform dramatically shortens the discovery-to-market timeline while stacking on top of existing varieties and trait packages. It’s a breakthrough solution to close the gap and meet urgent demand.” The funding will accelerate the rollout of its corn, soybean, rice, and forage grass traits—with a goal of capturing 10% of the non-transgenic seed trait market within five years. xTrait Platform Improves Productivity, Nutrition and Sustainability in Key Food Crops In 2025, BioLumic launched its first commercial xTraits Activation System at Gro Alliance’s seed production facility, enabling partners to integrate xTraits into elite corn inbreds and hybrids. Field trials have shown light-activated hybrid corn achieved over 20% yield gains, building on 8% gains in activated inbred parent lines. These hybrid traits will be commercially deployed in the U.S. market for the 2026 planting season. More than 10 additional traits are currently in development across multiple crops. BioLumic is also accelerating development of forage grass traits, representing a major opportunity to improve profitability and sustainability in pasture-based systems. These traits aim to boost pasture productivity and energy density—helping producers increase milk output, reduce supplemental feed use, and improve sustainability outcomes. Komal Mistry-Mehta, Ki Tua Fund Director and Fonterra’s Chief Innovation and Brand Officer, emphasized the potential of this partnership and value to NZ Inc: “Ki Tua Fund is focused on supporting startups that span Fonterra's value chain from on-farm productivity, manufacturing optimisation through to the future of food and health technologies. We know our dairy farmers need innovative solutions to increase profitability, and BioLumic's technology represents a potential game changer. In future, it could help Fonterra, and by extension NZ Inc, boost milk solids to manufacture into high value Ingredients and Foodservice exports.” These benefits are part of a broader push to align agricultural productivity with climate-smart practices. “BioLumic is creating a new category of seed traits that could help drive agricultural methane-reduction strategies, or what we call ‘Methane Moonshots’, like reducing the need for rice paddy flooding and changing the composition of pasture grass to cut enteric fermentation,” said Johanna Wolfson, General Partner at Azolla Ventures. “BioLumic delivers real-world climate advantages and economic value for farmers to create truly sustainable impact.” With fresh funding and strong commercial momentum, BioLumic is advancing a new generation of non-GMO trait innovation—scaling high-performing, sustainable traits that meet the needs of farmers, seed companies, and the global food system. About BioLumic: Founded in 2013, BioLumic is a U.S.- and New Zealand-based agricultural biotechnology company using light signaling as a programming language for plants. Its patented xTraits™ technology unlocks non-GMO genetic expression traits to enhance yield, composition, and crop resilience through a one-time, light-based seed application. BioLumic traits are scalable, fast to develop, and easily integrated into existing seed systems. Learn mores at www.biolumic.com or contact info@biolumic.com. Contact Details AgTech PR for BioLumic Jennifer Goldston jennifer@agtechpr.com Company Website https://www.biolumic.com

April 22, 2025 12:00 PM Central Daylight Time

Image

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

OSTX DAWN GSK ADCT

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031—a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology—using naturally occurring canine cancers as research models—are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that’s evolving faster than ever before. Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company’s lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company’s growth isn’t limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer. Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption—more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the “Exclusively Pediatric” designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One’s pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million—largely due to R&D and launch costs—the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer. GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK’s experimental antibody-drug conjugates (ADCs) that targets B7-H3—a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who’ve already gone through two lines of treatment. That’s a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK’s drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK’s pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year—including a relaunch of its blood cancer drug Blenrep—the company looks well-positioned to keep growing in high-need treatment areas. ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company’s growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company’s profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. For investors, ADC Therapeutics presents a compelling opportunity, particularly as the company progresses through key trials and works towards expanding the indications for ZYNLONTA. Despite the competitive landscape, ADC Therapeutics has demonstrated its ability to deliver results that could appeal to both oncologists and patients, positioning the company for future growth. The promising clinical data, solid cash position, and ongoing commitment to advancing its ADC technology make ADC Therapeutics a stock worth keeping on the radar. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 11, 2025 07:00 AM Eastern Daylight Time

Former ESPN NBA Insider Adrian Wojnarowski Joins Players Health’s NIL Advisory Board, Begins Brand Ambassadorship

Players Health

Players Health, the leading provider of athlete safety and insurance solutions, today announced the appointment of St. Bonaventure men’s basketball general manager and former ESPN NBA Insider Adrian “Woj” Wojnarowski to its NIL Advisory Board and as a brand ambassador. The partnership formally began on Friday, April 4, when Woj appeared on behalf of Players Health at the NCAA Men’s Final Four in San Antonio, Texas. Widely regarded as one of the most respected names in sports media, Woj joins the Players Health NIL Advisory Board after retiring from his award-winning role at ESPN, where he spent years breaking NBA news and guiding coverage across the network’s platforms. Now, as the general manager for St. Bonaventure men’s basketball, he oversees a broad range of responsibilities, including name, image, and likeness opportunities, transfer portal management, and alumni relations. “St. Bonaventure has given me opportunity to utilize three decades of relationships to create the greatest possible impact on the next generation of athletes,” said Wojnarowski. “Joining Players Health allows me to widen that circle even further, especially now, when NIL has opened remarkable doors. We want to ensure that while these athletes seize their opportunities, they do so with the safety and support they deserve.” Wojnarowski will join fellow industry leaders on the Players Health NIL Board of Advisors to drive strategic initiatives, engage in educational panels, and advance the Players Health mission at industry events. “Woj revolutionized sports journalism with his approach to reporting and relationships, and now he is bringing that same forward-thinking mindset to our team as one of the first GMs in college athletics,” said Tyrre Burks, Founder & CEO of Players Health. “NIL has fundamentally transformed the collegiate landscape, and there is no one better equipped to help us navigate this new era. His insights will be invaluable to our success as we work to develop solutions that keep athletes safe, supported, and empowered at every stage of their athletic career.” Players Health and Wojnarowski traveled to San Antonio for the NCAA Men’s Final Four, where Wojnarowski took part in a panel discussion on the evolution of the general manager role in collegiate athletics. The panel was held on Friday, April 4 at the Boggess Center during the Global NIL Conference hosted by Silver Waves Media. The announcement comes just three months after Players Health closed a $60 million Series C funding round to accelerate the expansion of their innovative athlete safety and insurance solutions across youth, recreational, collegiate, and professional sports. To learn more, visit: https://www.playershealth.com/ Players Health is a sports technology company providing digital risk management services, reporting tools and insurance products to sports organizations to empower them to stay ahead of their ever-changing safety and compliance responsibilities. Working towards establishing the safest environment for athletes, Players Health views the health and safety of athletes as a priority in today's sports landscape. Contact Details Hot Paper Lantern playershealth@hotpaperlantern.com Company Website https://www.playershealth.com

April 09, 2025 09:00 AM Eastern Daylight Time

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

OSTX DAWN CADL YMAB

The oncology sector in the U.S. is on the verge of a transformative breakthrough. With the cancer therapeutics market already valued at over $170 billion in 2024 and expected to exceed $500 billion by 2034, the industry is experiencing a surge of innovation driven by cutting-edge treatments like immunotherapies and targeted therapies. As cancer rates continue to rise, particularly among children and underserved populations, the urgency for novel solutions has never been greater. Investors are increasingly drawn to this rapidly evolving field, where new therapies are not just improving survival rates but offering hope where there was none. With breakthroughs happening at an unprecedented pace, the oncology space presents an exciting and compelling opportunity for those looking to invest in the future of healthcare. Now, let’s take a look at a few promising stocks in this expanding sector that could be worth keeping an eye on. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company that’s aiming to make a real difference in one of the toughest areas of medicine—osteosarcoma, a rare and aggressive bone cancer that mostly affects children and young adults. Their lead drug, OST-HER2, is not your typical cancer treatment. It's an off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to kickstart the body’s immune system into attacking cancer cells that express the HER2 protein. So far, the results have been very promising. In a Phase 2b clinical trial involving 39 patients with recurrent osteosarcoma that had spread to the lungs but was surgically removed, OST-HER2 showed a statistically significant boost in 12-month event-free survival—33% compared to 20% in similar patients who didn’t receive the treatment (p=0.0158). That’s a big deal in a cancer type where survival rates haven’t improved much in decades. "We believe OST-HER2 will make a significant difference in the treatment of osteosarcoma and welcome the opportunity to engage with FDA to get this investigational treatment to patients as quickly as possible,” said Paul Romness, CEO of OS Therapies. And the company is moving fast. OST-HER2 has already received special FDA and European designations, including: Rare Pediatric Disease Designation (RPDD) Fast Track Designation Orphan Drug Designation in both the U.S. and Europe These help speed up the development and review process. OS Therapies is now preparing to submit a Biologics License Application (BLA) to the FDA by late 2025, with the hope of receiving Accelerated Approval shortly after. In fact, the company recently requested a formal meeting with the FDA to agree on surrogate endpoints—essentially the key data the agency wants to see—in support of Breakthrough Therapy Designation and Accelerated Approval. That meeting is expected to happen in Q2 2025, and if all goes well, OST-HER2 could be approved by year-end. “We are excited to meet with the FDA... The goal is receiving Accelerated Approval for OST-HER2 by year-end 2025,” said Dr. Robert Petit, OS Therapies’ Chief Medical & Scientific Officer. There’s also potential upside beyond approval. If the drug is greenlit before September 30, 2026, OS Therapies is eligible for a Priority Review Voucher (PRV)—a valuable incentive from the FDA that the company could sell. A recent PRV sold for $150 million in February 2025, and that kind of windfall could help OS Therapies fund its next programs without needing to raise more money. OST-HER2 isn’t just being tested in people—it’s also been conditionally approved by the USDA for treating osteosarcoma in dogs, which naturally develop the disease in much the same way as humans. Dogs with cancer have been shown to respond to OST-HER2, and researchers are using this data to better understand which biomarkers might predict a strong response in people. Why does this matter? Because human and canine osteosarcoma share 96% genetic similarity. This growing field of Comparative Oncology is giving scientists like those at OS Therapies a unique window into how these therapies might work even before full human trials are complete. The treatment—and its story—will even be featured in the upcoming PBS documentary “Shelter Me: The Cancer Pioneers.” OST-HER2 is just the beginning. OS Therapies is also developing a next-generation Antibody Drug Conjugate (ADC) platform with tunable payloads—meaning they can design custom treatments for different cancers. This ADC program could offer future partnering or licensing opportunities, helping diversify the company’s pipeline. Financially, OS Therapies appears solid. The company completed both an IPO and private placement in 2024, raising $12 million and projecting enough cash to operate through mid-2026. With the heaviest clinical costs now behind them, OS Therapies expects lower spending moving forward. “We expect a significantly reduced outlay beginning in the second quarter of 2025,” said Chris Acevedo, CFO of OS Therapies. “We have reduced our burn rate substantially... and expect cash on hand to last into 2026.” Investors interested in emerging biotech should keep a close eye on OS Therapies (OSTX). With: Strong Phase 2b results Imminent regulatory milestones High-value PRV opportunity A unique canine-human comparative oncology angle A growing immunotherapy and ADC pipeline OSTX could be on the verge of something big. If OST-HER2 wins approval in late 2025, not only could it bring hope to children and families fighting this devastating disease, but it might also mark a major inflection point for the company’s valuation and visibility in the biotech space. Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company that focuses on developing off-the-shelf multimodal biological immunotherapies for cancer treatment. The company’s approach includes two distinct immunotherapy platforms: one using genetically modified adenovirus (CAN-2409) and the other using herpes simplex virus (CAN-3110). CAN-2409 is currently being tested in phase 2a clinical trials for non-small cell lung cancer (NSCLC), and it has completed phase 2a and phase 3 trials in pancreatic cancer and localized prostate cancer, respectively. Meanwhile, CAN-3110, from the herpes simplex virus platform, is undergoing a phase 1b clinical trial in recurrent high-grade glioma (rHGG). Candel also employs its enLIGHTEN Discovery Platform to identify new viral immunotherapies for solid tumors. In December 2024, Candel announced positive final survival data from a phase 2a clinical trial involving patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Patients treated with CAN-2409 alongside standard care experienced a significant median overall survival benefit of 31.4 months, compared to just 12.5 months in the control group. The data indicated that long-term survivors in the treatment group had a substantially better survival rate, even in metastatic disease, highlighting the sustained benefits of CAN-2409. This promising data led the FDA to grant both fast-track and orphan drug designations for CAN-2409 in pancreatic cancer. The company also revealed positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer in December 2024. In this trial, CAN-2409, combined with standard radiation therapy, resulted in a 30% reduction in the risk of recurrence or death compared to the control group. In addition, the treatment arm demonstrated an 80.4% pathological complete response rate in post-treatment biopsies, compared to 63.6% in the control group. These findings are seen as a significant step toward regulatory approval for CAN-2409 in the treatment of localized prostate cancer, and the study was conducted under a Special Protocol Assessment (SPA) with the FDA. Candel also provided an update on its phase 1b trial of CAN-3110 in recurrent high-grade glioma (rHGG). Data presented at the 6th Annual International Oncolytic Virotherapy Conference in October 2024 showed promising early survival outcomes, with three out of six patients surviving for over a year following repeated doses of CAN-3110. The company received both fast-track and orphan drug designations from the FDA for CAN-3110 in rHGG. Furthermore, Candel entered into a strategic partnership with IDEA Pharma, a biopharmaceutical strategy consultancy, in 2024. This collaboration will provide commercial insights into the development and commercialization of CAN-2409. Additionally, Dr. Elizabeth M. Jaffee, a leading pancreatic cancer expert, joined the company’s Research Advisory Board, enhancing its focus on advancing treatments for pancreatic cancer. In April 2025, Candel published the results of a phase 1b trial exploring the combination of CAN-2409 with nivolumab and standard care in newly diagnosed high-grade glioma patients. The data showed that the combination was well tolerated and resulted in extended survival for a subset of patients. A notable finding was the increase in T cell receptor (TCR) density and diversity, which correlated with improved survival outcomes. This reinforces the potential of CAN-2409 as a treatment for a wide range of solid tumors. Financially, Candel reported research and development expenses of $4.8 million for the fourth quarter of 2024, down from $7.3 million the previous year. General and administrative expenses increased slightly to $3.3 million for the quarter. The company posted a net loss of $14.1 million for the quarter, compared to a net loss of $11.1 million in the same period the previous year. For the full year 2024, Candel’s net loss amounted to $55.2 million, up from $37.9 million in 2023. As of December 31, 2024, the company had $102.7 million in cash and equivalents, which is expected to fund its operations into the first quarter of 2027. Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a biopharmaceutical company that is making significant strides in the fight against pediatric cancer, particularly high-risk neuroblastoma. Neuroblastoma is a rare and aggressive cancer that mainly affects children, and Y-mAbs is dedicated to improving the outcomes for patients who are facing this challenging disease. The company has developed DANYELZA (naxitamab), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. This breakthrough treatment offers hope to children who have exhausted other therapy options. One of the most promising aspects of Y-mAbs is its work with naxitamab, a treatment that has shown strong efficacy in clinical trials. According to a Phase 2 clinical trial published in Nature Communications, naxitamab demonstrated a 50% overall response rate (ORR) among patients with relapsed or refractory high-risk neuroblastoma. Notably, the therapy showed particularly strong results in targeting residual disease in the bone and bone marrow, which are common areas where cancer cells hide and resist traditional chemotherapy. Naxitamab is an anti-GD2 monoclonal antibody, meaning it targets the GD2 molecule found on the surface of neuroblastoma cells. This therapy is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that boosts the immune system to fight cancer. In clinical trials, naxitamab has shown manageable safety and promising efficacy, with many patients achieving a partial or complete response. In fact, 58% of patients with bone disease saw a positive response, making it an essential option for those who haven’t responded to other treatments. Y-mAbs has been actively working to expand the reach of DANYELZA globally. In 2024, the company reported significant revenue growth from its international markets, particularly in Europe and Asia. With DANYELZA now available in 69 U.S. centers and expanding into new regions, the company is well-positioned to bring this life-saving treatment to more children in need. As of early 2025, Y-mAbs has adjusted its business strategy to focus on expanding the clinical development of its Radiopharmaceuticals Platform, alongside continuing to drive the growth of DANYELZA. The company has a robust pipeline, including its innovative SADA PRIT technology, which could open up new avenues for treating solid tumors in pediatric cancer patients. Despite a net loss in 2024, Y-mAbs is focusing on cost efficiency and capital investment to fuel future growth. With a strong balance sheet and clear plans to expand its clinical and commercial efforts, Y-mAbs could offer significant upside potential for investors interested in the growing field of pediatric cancer therapeutics. For investors looking to support innovative treatments in pediatric cancer, Y-mAbs Therapeutics presents a unique opportunity, with a solid product, promising clinical data, and an evolving strategy for growth. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN ) is making significant strides in pediatric cancer treatment, tackling one of the most critical areas of unmet need in the oncology space. The company’s lead drug, OJEMDA (tovorafenib), is a promising targeted therapy designed to treat pediatric low-grade glioma (pLGG), a rare brain tumor that predominantly affects children. OJEMDA is a Type II RAF kinase inhibitor, targeting BRAF mutations that are common in pLGG. Approved by the FDA under accelerated approval, the treatment is a breakthrough in a field where treatment options have been limited. Since its launch in April 2024, OJEMDA has shown strong sales, with net product revenues of $57.2 million for the full year. In the first eight months post-launch, over 1,600 prescriptions were written, highlighting the demand for new therapies in this space. Day One has positioned OJEMDA as a cornerstone of its pipeline, and the company is already advancing its clinical strategy with a global, pivotal Phase 3 trial called FIREFLY-2. Full enrollment in the trial is expected by the first half of 2026, which could pave the way for further regulatory progress. Additionally, OJEMDA received Exclusively Pediatric designation from the Centers for Medicare & Medicaid Services in late 2024, which is expected to reduce the rebate percentage for the drug, further supporting its commercial viability. The company’s financial outlook appears solid, with a year-end 2024 cash balance of $531.7 million, providing a strong runway for future growth. Day One is also making progress in other areas, including its development of DAY301, a targeted antibody-drug conjugate (ADC), which has entered early-stage clinical trials. If successful, DAY301 could add to Day One’s growing pipeline and diversify its offerings in the pediatric oncology market. While Day One recorded a net loss in 2024, the company’s focus on expanding access to OJEMDA and advancing its pipeline positions it well for long-term success. For investors, Day One represents a unique opportunity to support innovation in pediatric cancer therapeutics, with a promising product, a strong pipeline, and a dedicated team pushing the boundaries of what’s possible in cancer treatment. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 09, 2025 07:00 AM Eastern Daylight Time

Centre for Neuro Skills Named to Newsweek’s America's Greatest Midsize Workplaces 2025

Centre for Neuro Skills

Newsweek named Centre for Neuro Skills (CNS), a leading provider of post-acute brain injury and stroke rehabilitation services, one of America’s Greatest Midsize Workplaces for 2025. CNS is the only neurorehabilitation provider listed in the healthcare category, achieving a 5-star rating. “We are incredibly honored to receive this recognition from Newsweek,” said David Harrington, president and CEO of CNS. “At Centre for Neuro Skills, we believe a great workplace not only is built on trust, respect and a shared commitment to growth but also fosters an environment where every employee can thrive, contribute and feel valued. This recognition is a testament to the power of our collective team’s dedication, collaboration and passion.” To determine award recipients, Newsweek partnered with Plant-A Insights to analyze more than 3.5 million online employee reviews and public data for 9,000 companies employing 500-1,000 individuals. A third-party data provider, Aniline, then leveraged its database of more than 120 key performance indicators, including leadership, integrity, compensation, career development, culture and belonging and work-life balance, to gain a comprehensive view of workplace performance and satisfaction for U.S.-based companies. CNS, with seven locations across California and Texas, recently announced a new location – its fifth in Texas – opening in late 2025 in Plano. The new clinic at 1640 Dallas Parkway Suite 3000 will include the full set of CNS services, including programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy with certified, highly trained clinical therapy staff. It will also feature advanced care technology, such as the ZeroG® Gait and Balance System and a Bioness Integrated Therapy System to aid in vision, motor and balance training. Focused on patient-tailored care and maximizing patient outcomes, CNS offers residential inpatient, day treatment, telerehabilitation and continued care programs to help patients regain independence through community reintegration and life skills building. Learn more about CNS’ programs here. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. Recognized as one of America's Greatest Midsize Workplaces 2025 by Newsweek, CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For moreinformation about Centre for Neuro Skills, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. Media, please note: To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. ### Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

April 02, 2025 08:01 AM Pacific Daylight Time

Image

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

ADIA FATE MESO CRSP

Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA’s recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA’s medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer’s disease. This is a major move in a rapidly growing field. According to ADIA’s CEO, Larry Powalisz, “Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.” This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, “We’re crafting a movement for reliability and excellence.” The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company’s treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA’s international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA’s asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA’s stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition’s combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate’s pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn’t require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate’s President of Research and Development, expressed his excitement over the results, saying, “We are pleased with the early clinical data, which continues to support the potential for disease transformation.” In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate’s pipeline doesn’t stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company’s strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil’s applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast’s CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, "Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy." Overall, Mesoblast’s strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company’s flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a "milestone-rich year" with major clinical updates expected across the company’s pipeline. While CASGEVY’s commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex’s commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 02, 2025 07:00 AM Eastern Daylight Time

Mid-Sized Data Centers Are Winning the Communications Battle While Many Industry Leaders Fall Behind

Hot Paper Lantern

Hot Paper Lantern (HPL), an integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth, released its latest data center industry study, "Who's Owning the Conversation?" The study analyzed over 35 companies spanning three key verticals: data center operators, cooling technology vendors, and network service providers. Data Center Operators included in the study: Aligned Data Centers • CloudHQ • Cologix • Compass Datacenters • COPT • CoreSite • DataBank • Digital Core REIT • EdgeConneX • Evoque Data Center Solutions • Flexential • OVHcloud • QTS Data Centers • Sabey Data Centers • STACK Infrastructure • Switch Inc. • Tencent Cloud • Vantage Data Centers Cooling Technology Vendors included in the study: Amana Heating & Air • American Standard • Bryant Heating & Cooling • Goodman Manufacturing • Heil Heating & Cooling • Nortek Global • Rheem • Rudd Heating & Cooling • York Air Conditioning • York International Network Service Providers included in the study: Adtran • Allied Telesis • Calix • Cambium Networks • D-Link • Inseego • MikroTik • TP-Link • Viavi Solutions • Zyxel Communications The research examines how these companies are shaping the mid-market narrative, identifies key areas for improvement, and offers data-driven strategies to help companies drive meaningful engagement. While some organizations take a proactive approach to their external communications by leveraging social media and media relations, others remain passive and allow third parties to shape their company’s narrative. This contrast sparks critical questions about how key sectors engage with their stakeholders and whether or not they will fully capitalize on the opportunities presented by the data center industry's unprecedented growth. "Data center operators have assumed that by just being active to generate some form of media coverage alone, this will translate to having a strong reputation. Our research proves that this is not the case. If you are not actively shaping your own story, someone else will do it for you, and often not in your favor," said Ed Moed, chief executive officer at Hot Paper Lantern. "The data center industry has grown exponentially in recent years, fueled by massive investments, technological advancement, and industry demand. Many companies have relied on that growth to define their value in the market, but as competition increases, a strong and strategic narrative is what will set organizations apart." Key Insights from the Study: Public Perception Doesn't Always Align with Coverage Volume – More coverage does not always translate to a stronger reputation. Nearly 10% of all social media conversations about the data center industry are negative. However, over 80% of that negativity comes from just two companies, and both are among the most active on social media. Their outsized presence has amplified criticism, highlighting the risks of lacking a strategic online narrative. Mid-Tier Operators Punch Above Their Weight in Influence — Despite having smaller budgets, some mid-tier data centers generate outsized impact. Based on revenue, the bottom half of companies analyzed averaged 7x more coverage and 15x more engagement, demonstrating the power of strategic messaging. Cooling Technology Vendors Are Missing Their Storytelling Opportunity — With sustainability and energy efficiency becoming critical topics, cooling providers remain surprisingly underrepresented in industry conversations. Ninety percent of cooling brands generate fewer than 500 media mentions across major platforms, creating a massive opportunity for those willing to participate in the discussion. Network Providers Are Failing to Engage the Data Center Audience — Despite playing a crucial role in data center operations, many network providers struggle to connect with their target audience. Most rely on generic product announcements rather than crafting narratives that will resonate with data center decision-makers. As a result, the top 40% of network providers account for 95% of the industry's digital visibility, leaving the majority with little influence in the conversation. "Cooling and network providers have expanded alongside the data center industry, yet their voice in industry discussions has not kept pace," said Moed. "As artificial intelligence accelerates demand for advanced infrastructure, these sectors must step forward. The companies that fail to establish themselves as industry leaders risk being overlooked, while those that actively shape the conversation will define the next phase of innovation and growth." For more details on the "Who's Owning the Conversation?" study, view the report here. HPL will continue tracking industry trends and key players, releasing quarterly reports about the evolving conversation. To stay informed on the latest findings and updates, visit www.hotpaperlantern.com and sign up for future reports. Hot Paper Lantern (HPL) is a New York City-based integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth. HPL partners with clients to find, engage, and form deeper connections with key audiences and stakeholders. For more information, visit www.hotpaperlantern.com. Contact Details Hot Paper Lantern emoed@hotpaperlantern.com Company Website https://hotpaperlantern.com/

April 01, 2025 10:00 AM Eastern Daylight Time